Clinical Trials
9 trialsNCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00019643 2023-10-31
Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer
National Institutes of Health Clinical Center (CC)
Terminated
NCT01326728 2018-06-06
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Terminated
NCT00984165 2018-05-02
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01088763 2014-11-05
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00933985 2014-05-01
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00101205 2014-02-24
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00036855 2013-01-17
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated